UNSPSC 51313406: Mebhydrolin or mebhydroline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SUK9B7XVY, chemically known as 5-benzyl-1,3,4,5-tetrahydro-2-methyl-2h-pyrido(4,3-b)indole but generally known as mebhydrolin, which bears US NIH Compound Identifier 22530. European Medicines Agency schedules Mebhydrolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08664MIG.

UNSPSC 51313406 Mebhydrolin or mebhydroline is a Commodity code that in practice encompasses the procurement of pharmaceutical products and related health-supply systems by state and local health agencies. Recent state and local opportunities tagged to this code show solicitation for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and therapeutic pharmacy initiative programs — a mix reflecting procurement of finished pharmaceutical goods, injectable medications, and supporting health-delivery infrastructure rather than raw chemical inputs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local government facilities including Oregon).

The code shows recent activity concentrated in Florida, Texas, and Minnesota. Representative recent solicitations include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities. The MMCAP RFP explicitly requires cGMP and Drug Supply Chain Security Act compliance, pricing through authorized wholesalers, and compliance with FDA expiration and shelf-life requirements, with awards weighted 75 percent on price competitiveness. The Seminole County procurement includes a three-month probationary termination window and potential FEMA funding with associated federal environmental compliance obligations.